(Q34010741)

30 July 2017

1 reference

title

Social anxiety disorder. (English)

1 reference

30 July 2017

0 references

Dan J Stein

2

0 references

author name string

Murray B Stein

series ordinal

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

30 July 2017

1 reference

30 July 2017

volume

371

1 reference

30 July 2017

issue

9618

1 reference

30 July 2017

page(s)

1115-1125

1 reference

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Different ages of onset in varieties of phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

1 reference

7 January 2021

Clinical practice. Social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Self-criticism and social phobia in the US national comorbidity survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Is "shy bladder syndrome" a subtype of social anxiety disorder? A survey of people with paruresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Social phobia subtypes in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Impact of generalized social anxiety disorder in managed care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Public-speaking fears in a community sample. Prevalence, impact on functioning, and diagnostic classification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

The Epidemiology of Social Anxiety Disorder in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Social phobia symptoms: prevalence, sociodemographic correlates, and overlap with specific phobia symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Prevalence of social phobia and its comorbidity with psychiatric disorders in Iran

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Childhood social anxiety disorder: from understanding to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Child anxiety in primary care: prevalent but untreated.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Disability and quality of life in social phobia: epidemiologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Epidemiology of social phobia in later life.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Functional impact and health utility of anxiety disorders in primary care outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

A direct-interview family study of generalized social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Heritability of social anxiety-related concerns and personality characteristics: a twin study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Low extraversion and high neuroticism as indices of genetic and environmental risk for social phobia, agoraphobia, and animal phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Social anxiety in primary care: hidden in plain view?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Using five questions to screen for five common mental disorders in primary care: diagnostic accuracy of the Anxiety and Depression Detector

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

The factor structure and screening utility of the Social Interaction Anxiety Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Mini-SPIN: A brief screening assessment for generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Brief measures to screen for social phobia in primary care pediatrics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Are we overpathologizing the socially anxious? Social phobia from a harmful dysfunction perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Childhood shyness and maternal social phobia: a community study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Psychiatric correlates of childhood shyness in a nationally representative sample.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Impact of psychiatric disorders on health-related quality of life: general population survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Philosophy and the DSM-III

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

1 reference

7 January 2021

Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Social anxiety in outpatients with schizophrenia: a relevant cause of disability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Comorbidity of anxiety disorders with anorexia and bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Body dysmorphic disorder and social phobia: cross-sectional and prospective data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Illicit drug use and anxiety disorders: findings from two community surveys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Associations in the course of personality disorders and Axis I disorders over time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: results from the national epidemiologic survey on alcohol and related conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Autism: a window onto the development of the social and the analytic brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Suffering in silence: why a developmental psychopathology perspective on selective mutism is needed

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Selective mutism and social anxiety disorder: all in the family?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Characteristics of Social Phobia Among Persons With Essential Tremor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Social phobia in adults with stuttering

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Familial aggregation of anxiety-related quantitative traits in generalized social phobia: clues to understanding "disorder" heritability?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

A polymorphism of the beta1-adrenergic receptor is associated with low extraversion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

COMT polymorphisms and anxiety-related personality traits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Relation of shyness in grade school children to the genotype for the long form of the serotonin transporter promoter region polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Influence of the serotonin transporter promoter gene and shyness on children's cerebral responses to facial expressions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Influence of RGS2 on anxiety-related temperament, personality, and brain function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

A Population-Based Twin Study of the Relationship Between Neuroticism and Internalizing Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Common Kibra alleles are associated with human memory performance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Anxiety disorders in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Low dopamine D(2) receptor binding potential in social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Dopamine reuptake site densities in patients with social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Striatal function in generalized social phobia: a functional magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

An insular view of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Inhibited and uninhibited infants "grown up": adult amygdalar response to novelty

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Neural correlates of genetically abnormal social cognition in Williams syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Reduced serotonin-1A receptor binding in social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Increased amygdala activation to angry and contemptuous faces in generalized social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Increased activation of the anterior cingulate cortex during processing of disgust faces in individuals with social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

The etiology of social phobia: empirical evidence and an initial model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Oxytocin increases trust in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Psychological and pharmacological treatments of social phobia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Pharmacotherapy for social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Psychometric properties of the Liebowitz Social Anxiety Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Antidepressants and the risk of suicidal behaviors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Cognitive-behavioral treatment of social phobia: new advances

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Do empirically supported treatments generalize to private practice? A benchmark study of a cognitive-behavioural group treatment programme for social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Prevention of childhood anxiety disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960488-2

7 January 2021

10.1016/S0140-6736(08)60488-2

Identifiers

DOI

1 reference

30 July 2017

1 reference